Articles
The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read More ›
A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read More ›
In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read More ›
Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics. Read More ›
BRAF/MEK-targeted therapy rechallenge in patients with BRAF-mutation–positive advanced melanoma whose disease progress on first-line BRAF-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients. Read More ›
In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read More ›
Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab. Read More ›
Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V600-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read More ›
The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read More ›